QIAGEN N.V. (QGEN) recently received FDA clearance for the NeuMoDx CT/NG Assay 2.0, growing its test menu for its integrated PCR-based clinical molecular testing systems NeuMoDx 96 and 288 in the United States. The Assay is designed to improve accessibility, affordability and timeliness in sexually transmitted infection (STI) testing in the country. The latest development will significantly boost the company’s Molecular Diagnostics business.About QIAGEN’s PCR-Based Clinical Molecular Testing SystemsThe NeuM ...

Venlo, The Netherlands, Jan. 11, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the fourth quarter and full year 2023. Press release date/time: Tuesday, February 6, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date/time: Wednesday, February 7, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time.  Three options for joining the conference call Register for call back connect ...

QIAGEN’s (QGEN) business is expected to get a boost from its expanded test menu and growth-driving strategic collaborations. However, overdependence on relationships with collaborative partners and foreign exchange headwinds are major downsides. The stock carries a Zacks Rank #3 (Hold) currently.QIAGEN’s long-term business strategy involves entering into strategic alliances as well as marketing and distribution arrangements with academic, corporate and other partners relating to the development, commerciali ...

Germantown, Maryland, and Venlo, the Netherlands, Jan. 08, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced the U.S. Food and Drug Administration (FDA) clearance for the NeuMoDx CT/NG Assay 2.0, growing its test menu for its integrated PCR-based clinical molecular testing systems NeuMoDx 96 and 288 in the United States. This assay is designed for direct detection of asymptomatic and symptomatic bacterial infections involving Chlamydia trachomatis (CT) and / or Nei ...

Venlo, the Netherlands, Jan. 07, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced a plan to return up to approximately $300 million (maximum EUR 273 million) to shareholders through a synthetic share repurchase that combines a direct capital repayment with a reverse stock split. QIAGEN has decided to implement the maximum $300 million value of the mandate given at the Annual General Meeting in June 2023, where shareholders gave virtually unanimous approval f ...

Venlo, the Netherlands, Muscat, Oman, and Riyadh, Saudi Arabia, Jan. 03, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced a significant expansion of its business in the Middle East region, which includes three major developments:  In early 2024, QIAGEN will open its regional headquarters in Riyadh, Saudi Arabia, in order to further strengthen its commercial footprint in the region.It has signed a memorandum of understanding (MoU) with the Ministry of Health of Sau ...

Financial Data and Key Metrics Changes - The company reported net sales of $476 million for Q3 2023, a decline of 5% compared to the previous year, while at constant exchange rates, sales were down 6% [20][14] - Adjusted earnings per share (EPS) for Q3 was $0.50 at constant exchange rates, exceeding the outlook of at least $0.48 [34][14] - For the first nine months of 2023, net sales grew 8% at constant exchange rates [13] Business Line Data and Key Metrics Changes - Non-COVID product sales rose 5% at constant exchange rates, supported by a 10% growth in highly recurring consumables, which accounted for over 85% of total sales [13] - The QuantiFERON TB test grew 25% at constant exchange rates, achieving sales of $100 million for the second consecutive quarter [15] - The QIAcuity digital PCR system saw over 40% sales growth at constant exchange rates, driven by new placements and increasing biopharma consumable sales [16] Market Data and Key Metrics Changes - The Americas region delivered a 1% growth in total sales, with a 4% growth rate for non-COVID business [32] - The Europe, Middle East, and Africa region experienced stronger growth, with non-COVID product sales rising at a double-digit rate [55] - The Asia Pacific Japan region saw a low single-digit decline in non-COVID sales, with China also experiencing a similar decline [55] Company Strategy and Development Direction - The company is focused on its pillars of growth, including expanding its key areas of expertise and investing in research and development [39] - The strategy includes maintaining a high level of profitability while investing around 10% of sales into R&D to drive future growth [17] - The company aims to leverage its established leadership in sample technologies and QuantiFERON while expanding into new growth areas like QIAstat diagnostic and QIAcuity [39][93] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's resilience amid a volatile macro environment, expecting solid sales growth and improved earnings in Q4 2023 [12] - The company reaffirmed its full-year outlook for 2023, targeting net sales of at least $1.97 billion and adjusted EPS of at least $2.07 [27][70] - Management is closely monitoring geopolitical and macroeconomic trends, including inflation and supply chain issues, which could impact future performance [27][46] Other Important Information - The company has a liquidity position of about $1 billion at the end of Q3 2023, down from $1.4 billion at the end of 2022 [36] - Operating cash flow for the first nine months of 2023 was $308 million, while free cash flow was $210 million [35] - The company repaid nearly $900 million of debt in the last 12 months, which has positively impacted interest expenses [58][60] Q&A Session Summary Question: How do lingering headwinds impact growth into 2024? - Management acknowledged challenges in the Chinese market and the impact of regulatory pressures but remains optimistic about the long-term potential of the diagnostics market [78][99] Question: What is the outlook for R&D investments in 2024? - Management indicated that R&D investments are expected to remain around 10% of sales, with potential for slight reductions depending on market conditions [127] Question: How is the NeuMoDx platform performing? - Management believes in the NeuMoDx platform's potential and is reviewing its performance while continuing to invest in its development [108][109] Question: What are the growth prospects for QuantiFERON? - Management expressed confidence in maintaining double-digit growth for QuantiFERON, supported by strong demand and ongoing R&D investments [114][124]

At this time, I would like to introduce your host, John Gilardi, Vice President, Head of Corporate Communications and Investor Relations at QIAGEN. Please go ahead. Hello, everyone. First of all, I would also like to thank Thomas for his significant contributions over his long and impactful career at QIAGEN. I would now like to hand back to Thierry. Roland Sackers With that, I'd like to thank you for your attention, hand back to John and the operator for the Q&A session. Thank you. We'll take our next quest ...

Company Participants Today, weÂ'll first have some remarks from Thierry and Roland and then move into the Q&A session. Before we begin, let me briefly cover our Safe Harbor statement. This call discussion and responses to your questions reflect the views of management as of today May 4, 2023. We will be making statements and providing responses to your questions that state intentions, beliefs, expectations or predictions of the future. Operator Thank you, John, and a very warm welcome to all of you and obvi ...

Solid results driven by 12% CER net sales growth in non-COVID product groups Regulation G: QIAGEN reports adjusted results, as well as results on a constant exchange rate (CER) basis, and other non-U.S. GAAP figures (generally accepted accounting principles), to provide additional insight on performance. In this presentation, adjusted results include adjusted net sales, adjusted gross income, adjusted net income, adjusted gross profit, adjusted operating expenses, adjusted operating income, adjusted operati ...